Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Eyepoint Pharmaceuticals Inc

EYPT
Current price
9.17 USD -1.39 USD (-13.16%)
Last closed 10.76 USD
ISIN US30233G2093
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 793 759 168 USD
Yield for 12 month +48.38 %
1Y
3Y
5Y
10Y
15Y
EYPT
21.11.2021 - 28.11.2021

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

34.9 USD

P/E ratio

Dividend Yield

Current Year

+46 018 000 USD

Last Year

+41 404 000 USD

Current Quarter

+10 524 000 USD

Last Quarter

+9 477 000 USD

Current Year

+41 386 000 USD

Last Year

+33 078 000 USD

Current Quarter

+9 788 000 USD

Last Quarter

+8 076 000 USD

Key Figures EYPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -114 583 800 USD
Operating Margin TTM -311.17 %
PE Ratio
Return On Assets TTM -31.39 %
PEG Ratio
Return On Equity TTM -74.68 %
Wall Street Target Price 34.9 USD
Revenue TTM 45 713 000 USD
Book Value 4.09 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -30.8 %
Dividend Yield
Gross Profit TTM 26 948 000 USD
Earnings per share -1.78 USD
Diluted Eps TTM -1.78 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -226.57 %

Dividend Analytics EYPT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EYPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 09.12.2020
Dividend Date 09.12.2020

Stock Valuation EYPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10.6528
Price Sales TTM 15.752
Enterprise Value EBITDA -11.4934
Price Book MRQ 3.4768

Financials EYPT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EYPT

For 52 weeks

5.86 USD 30.99 USD
50 Day MA 9.5 USD
Shares Short Prior Month 8 929 577
200 Day MA 14.36 USD
Short Ratio 15.84
Shares Short 9 171 397
Short Percent 20.09 %